guide and the shortly coming updated version is an appropriate time to review and compare it with other European guidelines in order to identify the main similarities and key features. METHODS: We compared the guiding key features and compared them based on the 32 key guideline features developed by Hjelmgren et al. RESULTS: No relevant differences were found between the Hungarian and the European guidelines in the major part (23) of the key features. The Hungarian guideline presented nearly the same methodological approach as the sample in the choice of comparator, time horizon, discount rate and financial impact analysis. We appraised relevant differences in the perspective of the FE studies, preferred analytical technical (CMA, CEA, CUA, CBA), systematic review of evidences, costs to be included, preferred outcome measure and delivery utility. The QALY is the preferred health outcome measure in cost utility studies almost in every European countries, however only the English and Scottish guidelines require only EQ-5D profile to deliver utility. In the new version of the Hungarian guideline the discounting factor will be changed from 5% to 3.7, the cost-effectiveness threshold will be explicitly determined (twofold and threefold of GDP per capita) and the direct comparisons will be preferred instead of indirect comparisons. CONCLUSIONS: Generally we concluded that the Hungarian guideline published in 2002 and 2014 did not undergo major version basically require the same approach and expectations as the European ones. Change in three main things (discount rate, cost-effectiveness threshold, direct comparison preference) makes our guidelines more elaborated that could help the rational decision-making. The explicitly determined cost-effectiveness threshold requires specification in the method of delivering utility in the future.

PHP170
THE SWISS HEALTH TECHNOLOGY ASSESSMENT (HTA) CONSENSUS: GUIDING PRINCIPLES
Schlander M1, Affolter C1, Sandmeier H1, Cueni T2, Cyger F3, Hebborn A4, Herren D1, Kaufmann S1, Kraft E8, Suter P9, Zitko P1, Cabieses B2, Pickett K3, Espinoza M3
1Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany, 2SantéSuisse, Solothurn, Switzerland, 3Interpharma, Basel, Switzerland, 4Chair of the EFPIA Economic and Social Policy Committee, Brussels, Belgium, 5Uppsala University, Uppsala, Sweden, 6Düker, Schindler & Funck, Zürich, Switzerland, 7Hoffmann-La Roche AG, Basel, Switzerland, 8Schulthess Klinik, Zürich, Switzerland, 9FMH Verbindung der Schweizer Ärztinnen und Ärzte, Bern, Switzerland, Swiss Academy of the Medical Sciences (SAMW), Basel, Switzerland
OBJECTIVES: Swiss Health Technology Assessment (HTA) initiatives have been fragmented, and official HTA processes by the Federal Office of Public Health (Bundesamt fuer Gesundheit, BAuG) have been limited to new technologies and interventions by the absence of a clear orientation of assessment and evaluation. METHODS: Therefore, SantéSuisse (the national association of sick funds) and Interpharma (representing the interests of the Swiss research-based pharmaceutical industry) initiated “SwissHTA”, a transparent and inclusive project designed to develop a national consensus how Switzerland might better use HTA. The process was led by a project team, with membership from Santésuisse (and Helansa), Interpharma (and Roche), the Swiss federal government (BAuG), the Swiss Medical Association (FMH), and the Swiss Academy of Medical Sciences (SAMW). After seven retreats of the project team and three workshops in the course of 12 months, the team reached a consensus. RESULTS: The Swiss HTA consensus statement emphasizes the need for a broad technology focus (covering both new and existing ones by specific approaches following a common set of core principles) and recommends opportunities for stakeholder involvement throughout the HTA processes. Primary evaluation criteria should be determined by the social preferences of the Swiss population, constrained by a prior normative commitment in line with constitutional provisions and the principles, rights-based legal tradition of Switzerland. The full range of health-related benefits should be evaluated, and assessment of clinical evidence should take into account the level of evidence that can reasonably be expected in a given context, rating the degree of confidence in outcomes in relation to the relevance and the magnitude of the effects observed. Economic viability should be evaluated based on budgetary impact and cost benefit ratios, whereas the consensus rejects the idea of uniform cost per QALY benchmarks. CONCLUSIONS: The Swiss HTA consensus combines a pragmatic approach with well-defined evolutionary options.

PHP171
HTA PRINCIPLES INCLUSION IN NEW EUROPEAN UNION MEMBER STATES
Tomé D1, Vanmansky M2, Marusakova E3
1Pharmacial Faculty at Comenius University, Bratislava, Slovak Republic, 2SLOVAHTA, Bratislava, Slovak Republic, 3CiglaxSmithKline Slovacia, Bratislava, Slovak Republic
OBJECTIVES: HTA has the increasing role in decision-making process in new EU member states. Health care systems microwellness causes differences in HTA exploitation and its characteristic, which is a key fear. Our objective is to make an overview about how within these countries to show similarities and its differences. METHODS: Literature search was done on governmental and governmental like sites to find HTA related Acts, regulation, guidelines or other relevant documents which describes HTA inclusion in new member states. First search was relevant to presence of HTA. In those of them where HTA is defined in legislation we compared several characteristics: model, role, type of HTA, role of pharmacoeconomic, threshold, discounting factor, sensitivity analysis and differentiation of approaches between therapeutic and prophylactic approaches. RESULTS: New EU member states (accessed in May 2004 or later) 10 applies HTA, 8 as light version, 2 as robust NICE like version. HTA has impactfull position in 5 of them (Poland, Slovenia, Slovakia, Estonia and Latvia). Only Poland applies full HTA approach. Rest of countries use narrow pharmacoeconomic approach. Threshold is officially published in primary legislation in 2 countries (Poland, Slovakia). Discounting factor varies between 3% and 5%. There was no difference recognized in evaluation of either therapeutic or prophylactic approaches. CONCLUSIONS: HTA form and role differ in new EU member states, but some similarities were identified. The next step is to consider the other factors like health care system, composition of costs and methods of its reimbursement by different bodies within relevant country. But certain common areas for cooperation could be established based on that.

HEALTH CARE USE & POLICY STUDIES - Patient Registries & Post-Marketing Studies

PHP172
CHALLENGES IN DEVELOPING A NEW SYSTEM FOR REGISTRATION OF PATIENT REGISTRIES
M. Schlanderski L1, Levy D2, Campion DM2, Levy MB3, Karl J4, Berliner E2, Khursna L1, Hossfeld F6
1Outcome, A Quintiles Company, Cambridge, MA, USA, 2Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA
OBJECTIVES: Patient registries are an important tool for many types of clinical research, including studies of comparative effectiveness, cost effectiveness, treatment patterns, patient outcomes, and natural history of disease. Use of registries is increasing, but there is no central database in the U.S. designed specifically to list patient registries. A searchable public database that is designed to provide information about patient registries would support research collaborations, reduce redundancies, encourage the efficient use of resources, and improve transparency in observational clinical research. The goal of this project, funded by the Agency for Healthcare Research and Quality, is to design and develop a Registry of Patient Registries (RoPR) system that meets the needs of a diverse set of stakeholders.

METHODS: Stakeholders from a broad range of organizations and with varying levels of familiarity with patient registries were identified and invited to participate in a series of web and in-person meetings to gather and refine the RoPR system requirements. Requirements were also revised through public comment and usability and pilot testing. Over 320 individuals participated in RoPR design activities.

RESULTS: Stakeholders identified a range of challenges facing the RoPR system. Challenges include improving understanding of the distinction between observational studies, patient registries, and other types of clinical research; determining how to provide useful information to assess registry quality; ensuring that registry listings are sufficiently complete; and motivating registry sponsors to list their registries on the RoPR. The RoPR requires data to be submitted to the system by registry proponents, who must verify the accuracy and completeness of their data. This ensures that the registry information is as accurate as possible. However, this process can be time-consuming and resource-intensive for some registries.

CONCLUSIONS: In response to stakeholder feedback, the RoPR was designed as an integrated system with ClinicalTrials.gov that collects information on registry purpose, classification, objectives, data collected, progress reports, and interest in collaboration and data sharing. Some challenges identified through stakeholder discussions were addressed in the system design. Other challenges must be addressed through education and collection of stakeholder feedback following the RoPR launch in September 2012.

HEALTH CARE USE & POLICY STUDIES - Population Health

PHP173
DISENGAGING THE RELATIONSHIP BETWEEN DISABILITY, SOCIOECONOMIC STATUS AND SOCIAL CAPITAL IN CHILE: A POPULATION-BASED STUDY
Zitko P1, Cabieses B2, Pickett K3, Espinoza M3
1Hospital Barros Luco, Santiago, Chile, 2Universidad del Desarrollo, Santiago, Yorkshire, Chile, 3York University, York, York, UK
OBJECTIVES: Disability is a global public health priority strongly related to socioeconomic status (SES). Social capital (SC) is a complex construct and little is known about how it relates to SES and disability in a middle-income country. This study’s purpose is to explore the relationship between physical disability and two dimensions of SC conflict analysis of Chilean National Health Survey-2010 (n=5037). Health outcome: Composite index of disability (continuous variable, range 0-100). Dependent variables: a) SES measures: household income per capita (tertiles), educational level (primary/secondary/higher), employment status (yes/no), and household assets index (tertiles); b) SC dimensions: interpersonal trust (3 variables), financial/emotional support (2 variables) and social participation (2 variables). After factor analysis, s 2 factors explained 60% variance (low uniqueness in all variables), with exception of social participation which was assess separately. After orthogonal-varimax-rotation, 2 continuous aggregated variables were considered for analysis: trust and social support. Kaiser-Meyer-Olkin=0.62; Cronbach alpha=0.70 for trust and social support, respectively. c) Demographic factors: age, sex, marital status, rural/urban area, education level (elementary/secondary/higher), and household assets index (tertiles). d) Multiple linear regression models analyzed in R. Confounding and multiple interactions terms were explored. RESULTS: Mean of disability was 18.8pts. A significant crude association between disability and SES was observed. All dimensions of SC were significantly associated with disability (Trust: -0.67pts, Support: -0.74pts. Adjusted regressions showed SES reduced the magnitude of its association to disability by 70% when dimensions of SC were added to the model, but remained significant. Social participation lost statistical significance in presence of SES. Multiplicative interaction terms were found between SES and education, providing additional higher chance to be disabled when being poorly educated and having low trust and support. CONCLUSIONS: There is a complex relationship between disability, SES and SC. Interactions between SES and SC significantly modify the chance of being disabled and this needs further consideration in the context of a middle-income country.
Barcelona, Spain,
34 for 1985 was negative but moderate (r = GDP per capita and the mortality rate by non communicable diseases. On the other hand, a positive correlation was observed between the GDP per capita and the mortality rate by communicable diseases, while a negative correlation was observed between the GDP per capita and the mortality rate by non communicable diseases. So a value at state level was measured by dividing the mortality rate by communicable diseases by the GDP per capita.

RESULTS: Data were drawn from the Canadian National Population Health Survey, with respondents being interviewed every two years between 1996/97 and 2006/07. Using growth curve modeling, HRQL trajectories for individuals aged 18 and over were associated with measures of BMI and LTPA. Growth models were conducted separately for males and females. RESULTS: Findings suggest that, for males, a category had little impact on baseline HRQL, with no impact on the rate of change in HRQL as men aged. Among women, higher BMI categories were associated with significantly lower baseline HRQL. However, BMI had no impact on the rate of change of HRQL. In contrast, LTPA had significant impact on HRQL, as well as the rate of change of HRQL, in women who were inactive or sedentary having much steeper declines in HRQL as they aged, as compared to individuals who were active in their leisure time. This was true for both men and women, regardless of BMI category. CONCLUSIONS: The results underscore the importance of LFTA in shaping trajectories of HRQL.

PHLP15 ECONOMIC PERFORMANCE AND EPIDEMIOLOGICAL TRANSITION IN MEXICO
Reyes-Lopez A
Mexican Children Hospital, Mexico City, Mexico
OBJECTIVES: To analyze the relationship between the economic performance and the epidemiological transition in Mexico for the period from 1985 to 2006.
METHODS: Data on Gross State Product (GSP) per capita and Gross Domestic Product (GDP) per capita were drawn from both unofficial and official sources, while mortality data by causes were extracted from vital statistics. Causes of death were grouped into two categories: communicable and non communicable diseases, excluding cancer because of the infectious etiology of some types of cancer. The epidemiological profile at state level was measured by dividing the mortality rate by communicable diseases by the mortality rate by non communicable diseases. So a value greater than one of this ratio reveals a predominance of communicable diseases and hence an epidemiological lag. Scatter plots and correlation coefficients were used to analyze the data. RESULTS: Throughout the study period a negative correlation was observed between the GDP per capita and the mortality rate by communicable diseases, while a positive correlation was observed between the GDP per capita and the mortality rate by non communicable diseases. On the other hand, the correlation between the epidemiological profile at state level and the GSP per capita for 1985 was negative but moderate (r = -0.53), but for 2008 the correlation between the same variables almost disappears (r = -0.029). CONCLUSIONS: For the whole country the relationship of both time series suggests interactions between economic performance and mortality by causes, but within the country the results reveal convergence of mortality running independently of economic conditions. This evidence may support the design of public policies to reduce inequalities in health.

PHLP16 SOCIOECONOMIC INEQUALITIES CONCERNING THE SELF-RATED HEALTH STATUS IN GREECE: A COMPARATIVE ANALYSIS OF POST-CRISIS EFFECTS
Kyriopoulou E1, Zavras D, Pavli E, Kyriopoulou J
Notimos Vouliagmenis General Hospital, Athens, Greece
OBJECTIVES: To examine the socioeconomic inequalities concerning the self-rated health status in 2006 and in 2011. Thus, a comparison between the findings will highlight the changes concerning this topic in times of economic crisis.
METHODS: The research was conducted on the cross-sectional basis, which took place in Greece in 2011, and the sample size was 4003 and 6569 respectively. Moreover, a random, stratified sampling was applied in both cases, which took into account the age, the gender, the urbanization rate and the geographical region. RESULTS: Initially, the self-rated health status was measured with a Likert scale (0: very bad, 2: bad, 3: moderate, 4: good, 5: very good). However, it was dichotomized into two major scales (0: very bad, bad, and moderate, 1: good and very good), in order to facilitate the methodology. Afterwards, the Concentration Index (Ranking Variable: Income) was estimated at 0.15 in 2011, and the new Concentration Index was approximately 0.07. CONCLUSIONS: Despite the fact that the small positive values of this index (which approximate the zero) do not indicate important inequalities, there are some key conclusions concerning these findings. Specifically, it is noteworthy that the high-income people seem to have a higher health status. In addition, the decrease of the Concentration Index in 2011 highlights the impact of economic crisis on health status of middle and upper class.

HEALTH CARE USE & POLICY STUDIES - Prescribing Behavior & Treatment Guidelines

PHLP17 CHARACTERISTICS OF PATIENTS NOT CONSUMING PHARMACOLOGICAL RESOURCES DUE TO A LACK OF DRUG PRESCRIPTION DURING THEIR HOSPITAL ADMISSION
Salls J1, Grau S2, Luque S3, Mateu de Antonio J3, Ferández O3, Urbina O3, Mojal S4
1Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain; 2Hospital del Mar, Barcelona, Spain; 3Hospital del Mar, Barcelona, Spain; 4Research Department of the Drug Registry of Catalonia (DRC), Medical and Surgical, Hospital del Mar, Barcelona, Spain
OBJECTIVES: A high proportion of patients consume pharmacological resources during a hospital admission but little is known about the characteristics of those not receiving a drug prescription (DP). The aim was to assess independent patient’s factors associated to a non-DP drug prescription. Both an observational study including all patients studied in an admitted teaching hospital during 2010. Exclusion criteria: direct admission at the Intensive Care Unit. Data collected: patients with and without a DP, demographics, programmed or urgent admission, Charlson index, length of hospital stay, type of hospital stay (ODG), type of surgery (medical or surgical), DRG weight, readmission, mortality. Statistical analysis: Univariate analysis were performed, using Chi-Square test, Fisher exact Test and Mann-Whitney U test. A binary logistic regression was applied to identify independent factors of the model with the area under the curve and the characteristics ROC curve (AUC). RESULTS: Patients: 16,485. Included: 15,750. Without a DP: 1,822 (11.6%). Univariate: Patients with and without a DP; Age: 55.40 (+24.26) vs 23.70 (-39.89)(p < 0.001); Male: 6830(49.0%) vs 9720(33.3%)(p < 0.001). Urgent admission: 5,183(37.2%) vs 1,534(73.2%)(p < 0.001); Charlson (0): 7,724(51.5%) vs 1,529(0.001). LOS: 8.18(1.63)(p < 0.001); DRG weight: 1.79(1.87) vs 0.84(1.55)(p < 0.001); Readmission: 3,786(27.2%) vs 194(10.6%)(p < 0.001); mortality: 3832(7%) vs 472(6.6%)(p < 0.001). Independent factors related to non-DP: age < 18 years (OR: 4.83, CI95%: 2.97-5.59, p < 0.001); Charlson (0): OR(1.65, CI95%: 1.37-1.92, p < 0.001). LOS < 2 days (OR: 13.71, CI95%: 11.70-16.66, p < 0.001), medical DRG (OR: 2.772, CI95%: 2.354-3.264, p < 0.001). AUC: 0.917 (CI95%: 0.910-0.924, p < 0.001). CONCLUSIONS: Paediatric population, an urgent admission, a low comorbidity status, a short LOS and the gender factors were related to a hospital admission. These patients could be managed in an ambulatory setting, which would help to reduce the economic burden in hospitals.

PHLP18 VALIDITY OF SELF-REPORTED HEALTH CARE UTILIZATION: TOWARDS A RESEARCH CONSENSUS
Chernyak N1, Jülich F1, Droste S1, Icks A1, Dintsios CM2
1Hennh-Heine University Düsseldorf, Düsseldorf, Germany, 2German Association of Research-based Pharmaceutical Companies (vhf), Berlin, Germany
OBJECTIVES: Health care costs are often estimated using self-reported health care utilization data. The validity of these estimates is, however, challenged by the validity of self-reported data. The objectives were: (1) to review research findings on the validity of self-reported health care utilization focusing on factors affecting it; (2) to delineate implications for future research. METHODS: A systematic literature survey was conducted in relevant literature databases. The identified publications were screened by predefined inclusion and exclusion criteria. Information on the accuracy of self-reported health care utilization was extracted from all included publications and analyzed. RESULTS: Te accuracy of self-reporting varies strongly across different types of resource use. Underreporting appears to be the most common problem and increases with the frequency use and length of recall period. Comparisons across studies are difficult because of substantial heterogeneity in study populations, measurement methods and validation approaches (“gold standard” used, definition of agreement between self-reports and other data sources). Most identified validation studies are characterized by non-experimental designs. Consequently, the influence of modifiable attributes of data collection (e.g. recall period) on the accuracy of self-reported data can only be analyzed by comparison among different studies. CONCLUSIONS: More experimental studies are needed to better quantify the impact of modifiable attributes of data collection, such as for example different recall periods and modes of questionnaire administration, on quality of self-reported health care utilization.

PHLP19 EVALUATION OF PRESCRIBING PATTERNS OF CLINICIANS IN GOVERNMENT TEACHING HOSPITAL IN PAKISTAN
Ahmad M, Ahmad M, Ahmad M
The Islamia University of Bahawalpur, Bahawalpur, Punjab, Pakistan
OBJECTIVES: Irrational prescribing is a usual practice in developing countries like Pakistan. To analyze the prescribing pattern including both the layout of prescription and types of drugs prescribed by the doctors in a government teaching hospital in Pakistan. METHODS: Prescriptions (n = 830) from a government teaching hospital were collected randomly over a period of three months and evaluated retrospectively. The data were analyzed to assess the quality of prescription including both the layout and the type of drugs prescribed following the guidelines of WHO. RESULTS: Measurement of prescription quality of the prescriptions of the prescriptions was unsatisfactory. Clarity of written instructions on how to take the medicines was inadequate. 41% of the prescriptions were without the age of the patient which includes 23% of pediatric prescriptions. Thirteen percent (13%) of medicines were prescribed with their uncommon abbreviated names. The average numbers of drugs per prescription were found to be 3.57. Seventy seven percent (77%) of the drugs were prescribed with their generic names. Polypharmacy was the norm, with more than half (53.9%) of the prescriptions containing at least 3 medicines. Eight percent (8%) of prescriptions included a combination of at least two medications and 33% of analgesics/antipyretics, Penicillins, Cephalosporins, Quinolones Metrodilazol and Tetracyclines were commonly prescribed antimicrobials, respectively. The high-priced antimicrobials were frequently prescribed without culture and sensitivity studies. CONCLUSIONS: This study concludes that quality of prescriptions in terms of layout and content of the drugs prescribed is inadequate requiring continued medical education. To enhance the legibility computer generated prescriptions should be promoted.